Evidence map›Paper›PMID 42801716›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Chemical Screening Identifies Danofloxacin as a Self-Renewal Agonist of Embryonic Stem Cells through Alleviation of HDAC1-Mediated Deacetylation of Tert and Prdm10.

Yan Zhang, Junxiang Ji, Baoxing Dong, Zhenhua Zhu, Xucheng Lv, Peng Chen, Wenqiang Liu, Min Zhou, Shou-Dong Ye

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan Zhang *Center for Stem Cell and Translational Medicine, School of Life Sciences and Medical Engineering, Anhui University, Hefei, China.
Junxiang Ji *Center for Stem Cell and Translational Medicine, School of Life Sciences and Medical Engineering, Anhui University, Hefei, China.
Baoxing Dong *Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Frontier Science Center For Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Zhenhua Zhu *Department of Clinical Laboratory, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xucheng LvCenter for Stem Cell and Translational Medicine, School of Life Sciences and Medical Engineering, Anhui University, Hefei, China.
Peng ChenCenter for Stem Cell and Translational Medicine, School of Life Sciences and Medical Engineering, Anhui University, Hefei, China.
Wenqiang LiuShanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Frontier Science Center For Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Min ZhouDepartment of Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Shou-Dong YeCenter for Stem Cell and Translational Medicine, School of Life Sciences and Medical Engineering, Anhui University, Hefei, China.ORCID https://orcid.org/0000-0003-1864-8561

Funding

Health Research Project of Anhui Province, China AHWJ2024Aa40017National Natural Science Foundation of China 32270847National Natural Science Foundation of China 82241050
6 · The paper itself

Abstract

While significant advances have been made in maintaining stem cell pluripotency, the successful establishment of embryonic stem cells (ESCs) from various animal species in vitro remains challenging. This highlights the need for further optimization of culture conditions. Through compound library screening, we identified Danofloxacin, a small molecule, as a promoter of mouse ESC stemness. Danofloxacin enhances the formation of undifferentiated colonies and the generation of chimeric mice. Mechanistically, it suppresses HDAC1 expression and activity, resulting in increased acetylation of histone H3 at lysines 9 (H3K9ac) and 27 (H3K27ac), which in turn upregulates the expression of Tert and Prdm10. Functional assays revealed that overexpressing Tert or Prdm10 mimics Danofloxacin's effect on ESC self-renewal, whereas knockdown of either gene disrupts this process. Moreover, the elevated levels of H3K9ac and H3K27ac activate the PI3K/AKT and HIF-1α signaling pathways, both of which contribute to the transcriptional upregulation of Tert and Prdm10. These findings offer new insights into the pluripotency regulatory network and propose potential strategies for isolating ESCs from other species in vitro.

Indexed as

danofloxacinembryonic stem cellspluripotencyself‐renewal

Identifiers

PMID42801716
PMCPMC13616382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.